On behalf of the British Association of Dermatologists, thank you for the opportunity to comment on the Final Appraisal Determination.

The only point we would like to make is that whilst dose escalation may not be cost effective for the whole population, it may benefit some patients (e.g. those who have had a partial response or with inadequate drug exposure – mainly obesity-related), particularly where other options may be relatively contraindicated (e.g. in conception and pregnancy) or in people who have concomitant psoriatic arthritis where the joints have completely responded.

Profs Nick Levell & Catherine Smith
On behalf of Therapy & Guidelines sub-committee